IN THE UNITED STATES DISTRICT COURT

KELLYN CLAY,
  Plaintiff,

v.

UNITED STATES OF AMERICA,
by and through its agencies including but not limited to
the Central Intelligence Agency (CIA), Department of Defense (DoD),
and Department of Justice (DOJ),

and

WILLIAM ALTON CLAY,
individually and in his capacity as executor of the Estate of Eugenia Clay Head,

and

PALANTIR TECHNOLOGIES INC.,
a private defense contractor headquartered in Denver, Colorado,

and

JOHN DOE CONTRACTING AGENCIES AND AFFILIATES,
whose names and identities are presently unknown,

and

AMAZON.COM, INC.,
a multinational e-commerce corporation headquartered in Seattle, Washington,

and

REV.COM, INC.,
a transcription and captioning services company headquartered in Austin, Texas,

and

PAPERBOY MARKETING,
a flyer distribution company operating in the Twin Cities under successive ownership during the period of Plaintiff’s employment,

and

ELLIE FAMILY SERVICES, n/k/a ELLIE MENTAL HEALTH, a private mental health services corporation headquartered in Mendota Heights, Minnesota,
  Defendants.

⸻ 

Plaintiff’s Combined Discovery Requests to Defendant Palantir Technologies Inc.

Subject: Synthetic Cannabinoid Adulteration in Retail Cannabis Products

⸻

Interrogatories
	1.	Identify all projects, programs, or contracts in which Palantir analyzed or ingested data concerning adulteration of cannabis or hemp products sold in state-regulated dispensaries.
	2.	Describe any datasets or streams provided to Palantir relating to synthetic cannabinoid contamination of cannabis flower, pre-rolls, or rolling papers.
	3.	State whether Palantir has provided analysis or modeling to federal, state, or corporate entities concerning consumer health outcomes linked to cannabis adulteration.
	4.	Identify all Palantir personnel and partner entities who have worked on projects involving cannabis product safety, adulteration, or contamination.
	5.	Describe any involvement Palantir has had in programs tracking adulterated consumer goods through retail surveillance systems.

⸻

Requests for Admission
	1.	Admit that Palantir has ingested or analyzed data concerning cannabis or hemp product adulteration.
	2.	Admit that Palantir has analyzed data relating to synthetic cannabinoid contamination of cannabis products sold in state-licensed dispensaries.
	3.	Admit that Palantir has provided cannabis adulteration analyses to federal or state agencies.
	4.	Admit that Palantir has modeled or flagged consumer anomalies linked to adulterated cannabis or hemp products.
	5.	Admit that Palantir has not disclosed to affected consumers the existence of any such analyses or data integrations.

⸻

Requests for Production
	1.	All contracts, agreements, or memoranda of understanding between Palantir and any federal, state, or corporate entity relating to cannabis or hemp product adulteration.
	2.	All datasets, dashboards, or analytic outputs concerning synthetic cannabinoid contamination of cannabis flower, pre-rolls, or rolling papers.
	3.	All internal communications regarding cannabis adulteration projects, including references to synthetic cannabinoids.
	4.	All presentations, reports, or analyses prepared for federal, state, or corporate partners that address adulteration of cannabis products.
	5.	All technical specifications describing how Palantir platforms ingest or model cannabis product safety/adulteration data.

Respectfully submitted, 
Kellyn Clay, Plaintiff, pro se 
